Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DISCOVER: F/TAF for HIV Pre-Exposure Prophylaxis in MSM and TGW
NCT02842086Phase 3Terminated
- Sponsor
- Gilead Sciences
- Start
- Sep 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Gilead Sciences. Started Sep 2016; status: terminated.
02
Drugs
emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02842086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842086.